- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01285388
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
June 25, 2018 updated by: Yungjin Pharm. Co., Ltd.
A Dose Double-blind,Placebo-controlled,Single Dosing,Dose-escalation Clinical Trial to Investigate the Safety,Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single oral dose.
Study Overview
Detailed Description
Safety/ Tolerability evaluation
-Adverse events, Physical examinations, Vital signs, ECG (including continuous ECG monitoring), Laboratory tests (including hematology, chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC
Pharmacokinetic Evaluation
- Serial blood samples and urine collections for pharmacokinetic evaluations will be conducted between 0 (pre-dose) and 96 hours after a single oral dose.
- Blood sampling time pre-dose, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h, 48h, 72h post-dose
- Urine collection time 0h - 6h, 6h - 12h, 12h - 24h, 24h - 48h, 48h - 72h
- Evaluation parameters AUClast, AUCinf, Cmax, Tmax, t1/2, Vd/F, CL/F, Ae, fe, CLR
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB) - approved informed consent prior to performing any of the screening procedures
- Healthy Korean male volunteers, age ranged 20 to 45 years (both inclusive)
- A subject with body weight between 60 kg (inclusive) and 90 kg (exclusive) and body mass index (BMI) between 18.5 (inclusive) and 25 (exclusive). ☞ BMI (kg/m2) = weight (kg) / {height (m)}2
- Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the laboratory reference ranges for the relevant laboratory tests (unless the investigator considers the deviation to be irrelevant for the purpose of the study)
Exclusion Criteria:
- A subject with history of allergies including drug allergies (aspirin, antibiotics, etc.), or history of clinically significant allergies
- A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease
- A subject with history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
- A subject whose hemoglobin(Hb) level < 12 g/dL
- A subject with fasting plasma glucose (FPG) level ≤ 70 mg/dL or ≥ 126 mg/dL
- A subject with HbA1c level ≥ 7.0 mmol/L
- A subject whose systolic blood pressure (SBP) ≤ 90 mmHg or ≥ 140 mmHg, diastolic blood pressure (DBP) ≤ 40 mmHg or ≥ 90 mmHg or pulse rate (PR) ≥ 100 /min after at least 5 min sitting
- A subject with history of drug abuse or positive urine drug screening test
- A subject who has taken any prescribed medication or herbal compounds within 14 days prior to the study drug administration. In addition, a subject who has taken any over-the-counter drug or vitamin supplements within 7 days prior to the study drug administration (However, investigators can judge the subject, who has taken the medications during those periods above, eligible for the trial if all other conditions are satisfied.)
- A subject who has participated in any other clinical trial either for investigational or marketed drugs within 8 weeks before the study drug administration
- A subject who has donated or had loss of ≥ 400 mL of blood within 8 weeks prior to start of administration of study drug
- A subject who consumes more than 21 units of alcohol per week or unable to stop drinking throughout the study period.
- A smoker (except for whom quitted smoking prior to the drug administration for at least 3 months)
- A subject who heavily takes caffeine or caffeine-containing products, grapefruit, grapefruit juice, grapefruit-containing products
- A subject with unusual dietary habit
- A subject who was previously assigned to treatment during this study
- The investigator judges the subject not eligible for the study after reviewing clinical laboratory results or other reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Other Names:
|
Experimental: MB12066 10mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Other Names:
|
Active Comparator: MB12066 30mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Other Names:
|
Active Comparator: MB12066 100mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Other Names:
|
Active Comparator: MB12066 150mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Other Names:
|
Active Comparator: MB12066 200mg
|
MB12066 10mg, 100mg/tab.
once oral dose MB12066 10, 30, 100, 150, 200mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety/ Tolerability evaluation
Time Frame: from day-1 to day8-10
|
Adverse events, Physical examinations, Vital signs, ECG (including continuous ECG monitoring), Laboratory tests (including hematology, chemistry, coagulation, PBS, NAD(P)+/NAD(P)H ratio, urinalysis), CIC
|
from day-1 to day8-10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Evaluation
Time Frame: between 0 (pre-dose) and 96 hours after a single oral dose.
|
|
between 0 (pre-dose) and 96 hours after a single oral dose.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kyung-Sang Yu, Professor, Clinical Research Institute of Seoul National University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2010
Primary Completion (Actual)
January 1, 2011
Study Completion (Actual)
January 1, 2011
Study Registration Dates
First Submitted
July 4, 2010
First Submitted That Met QC Criteria
January 26, 2011
First Posted (Estimate)
January 28, 2011
Study Record Updates
Last Update Posted (Actual)
June 27, 2018
Last Update Submitted That Met QC Criteria
June 25, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MB12066_001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on MB12066
-
Yungjin Pharm. Co., Ltd.CompletedMetabolic SyndromeKorea, Republic of
-
Yungjin Pharm. Co., Ltd.KT&G CorporationCompletedObesity | Metabolic SyndromeKorea, Republic of
-
Yungjin Pharm. Co., Ltd.TerminatedNonalcoholic Fatty Liver DiseaseKorea, Republic of